Press releases

Alzheimer’s disease is a neurodegenerative disorder that would not normally affect mice in their natural habitat. Despite this, the animals are indispensable when it comes to Alzheimer’s research. Novel mouse models are required to more clearly display the complex interactions and relations involved in Alzheimer’s disease; models that would lead to a better understanding of the causes and progression of the disease and – it is hoped – that would facilitate the development of promising therapies and would enable the disease to be diagnosed as early as possible. Researchers from the Fraunhofer Institute for Cell Therapy and Immunology IZI have now taken an important step forward in creating more appropriate mouse models. At the beginning of November, the team from Halle (Saale), Germany, attended the Society for Neuroscience’s annual meeting, where they presented for the very first time their latest advances in the development of new animal models, addressing a wide scientific audience.

In August 2018, a pilot plant for low-energy electron irradiation of liquids was installed and commissioned at Fraunhofer IZI in Leipzig. This plant is designed to contribute to scaling up an innovative procedure for inactivating viruses and other pathogens from laboratory to industrial scale.

On 19 October 2018, the Fraunhofer project center "Microelectronic and Optical Systems for Biomedicine" (MEOS) celebrated its opening in Erfurt, Thuringia, together with top representatives from the fields of politics, science and business. Three Fraunhofer institutes – the Fraunhofer Institute for Photonic Microsystems IPMS, the Fraunhofer Institute for Applied Optics and Precision Engineering IOF and the Fraunhofer Institute for Cell Therapy and Immunology IZI – will conduct joint research projects into new biomedical applications in this area in future, working closely together with business partners.

This year’s Fraunhofer Life Science Symposium was held on September 27, 2018 in honor of institute founder Professor Frank Emmrich. Professor Emmrich set up the Fraunhofer Institute for Cell Therapy and Immunology IZI in Leipzig back in 2005. In December 2017, after 13 years of success and strong growth, he handed over the reins to Professor Ulrike Köhl. 150 invited guests, companions, longstanding research partners, colleagues and members of staff came together with various speakers to look back at key milestones in the career of the renowned immunologist. President of the Fraunhofer-Gesellschaft Professor Reimund Neugebauer also expressed his thanks.

Novartis and Fraunhofer IZI announced today that a further agreement has been concluded between Novartis and the Fraunhofer Institute for Cell Therapy and Immunology in Leipzig for the manufacture of the CAR (chimeric antigen receptor)-T cell therapy for patients in Europe over the next few years. The collaboration that began back in 2015 to manufacture CAR-T cell therapies for patients taking part in clinical trials initiated by Novartis is therefore being successfully expanded and continued.

Researchers from the Fraunhofer Institute for Cell Therapy and Immunology IZI, Harvard University and the University of Cambridge probing the mysteries of how DNA molecules can self-assemble into complex structures have found ways of tuning the assembly process to make it more efficient and significantly faster.

Nucleic acids such as DNA and RNA are being drawn upon more and more in modern medicine, with gene sequences, for instance, being applied in gene therapies and DNA vaccines. The latter of these offer multiple advantages compared with traditional vaccination methods as they are quick to manufacture, easy to adapt and are highly stable. Moreover, the coded antigens are produced by the body itself, meaning they are correctly modified and/or folded. Immunization using DNA vaccines activates both the cellular and the humoral immune defense, i.e. the production of antibodies by the B-lymphocytes, thus helping to provide effective protection against pathogens.

Between 2011 and 2017, the Fraunhofer Institute for Cell Therapy and Immunology assisted American biotech company Northwest Biotherapeutics, Inc. in the conduct of a phase three clinical trial investigating the efficacy of the new DCVax®-L cell therapy in the treatment of glioblastomas. Fraunhofer IZI was responsible for preparing the investigational medicinal products for the European part of the trial. On May 29, 2018, the company published initial clinical findings in the Journal of Translational Medicine.

Sugar can have many negative effects on the body. Overconsumption can give rise to obesity, high blood pressure and even diabetes. But there is more to sugar than meets the eye. For their next joint project, scientists from the Fraunhofer Institute for Cell Therapy and Immunology IZI and the Max Planck Institute of Colloids and Interfaces (MPIKG) have set their sights on polysaccharides. The two institutes will join forces to investigate how the arrangement of sugar molecules on DNA structures can be utilized to develop new antimicrobial agents. Planned to span a four-year period from May 2018, the "Glyco3Display" research project is being funded as part of the cooperation program between Fraunhofer and Max Planck.

On 15 May 2018, international researchers and physicians gathered at Fraunhofer IZI to discuss new options in the treatment of infectious diseases affecting the cardiovascular system. The discussions focused in particular on adsorber systems, which wash out gram-negative bacteria using lipopolysaccharide (LPS) adsorbers in the blood.